Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248
Recruiting
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Connecticut Eye Consultants P.C. /ID# 235862, Danbury, Connecticut
Conditions: Open-angle Glaucoma, Ocular Hypertension
Register for Updates
Pain and Weight Treatment: Development and Trial of PAW
NCT04046562
Recruiting
Pediatric weight management efficacy is impacted by failure to complete treatment protocols and, for those that do complete treatment, a return to unhealthy behaviors. This project tests whether treating pain, a common comorbid condition to pediatric obesity, will enhance treatment. This study will generate results that can be translated into immediate improvements in care for families seeking treatment for pediatric obesity.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
07/09/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Obesity, Adolescent, Pain, Chronic, CBT
Register for Updates
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
ALL
Ages:
All
Trial Updated:
07/09/2025
Locations: Yale University (Adults and Pediatrics), New Haven, Connecticut
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Genomic Profiling in Cancer Patients
NCT01775072
Recruiting
The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/09/2025
Locations: St. Vincent (Data Collection Only), Bridgeport, Connecticut
Conditions: Solid Tumors, Hematologic Cancers
Register for Updates
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762
Recruiting
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Register for Updates
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
NCT06648655
Recruiting
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
NCT06521762
Recruiting
This is a randomized, double-blind, placebo-controlled, two-arm phase 2 study of etrasimod plus corticosteroids versus placebo plus corticosteroids for the treatment of IMDC CTCAE v5.0 grade ≥ 2 due to ICI therapy alone (α-PD-(L)1 monotherapy or combined with another ICI, such as α-CTLA-4 or α-LAG-3) or ICI plus an oral tyrosine kinase inhibitor that in the opinion of the treating physician requires treatment with corticosteroid-based immunosuppression and does not require immediate secondary im... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Immune Checkpoint Inhibitor-Related Diarrhea and Colitis
Register for Updates
Evaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation
NCT06407427
Recruiting
This study aims to evaluate the effectiveness of a mobile application in improving postoperative rehabilitation outcomes among patients undergoing orthopedic surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Yale New Haven Hospital Saint Raphael's Campus, New Haven, Connecticut
Conditions: Spine Degeneration, Hip Arthritis, Knee Osteoarthritis, Hip Fractures
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: Yale Universtiy, New Haven, Connecticut
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT06377852
Recruiting
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/07/2025
Locations: Smilow Cancer Hospital Care Center - Derby, Derby, Connecticut
Conditions: Metastatic Breast Cancer
Register for Updates
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
NCT06371404
Recruiting
The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurrent PTSD and AUD with control groups. While there are a large number of studies conducted in preclinical stress and addiction models, these findings have not been translated to people living with these... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/07/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Alcohol Use Disorder, Post Traumatic Stress Disorder
Register for Updates
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407
Recruiting
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Register for Updates